Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
24/7 Wall St. on MSN2d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...
Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...
"We will continue to work closely with the authorities toward approval in the EU." Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor ...
The team are now recruiting patients into a new trial called LITESPARK-022 that combines Keytruda with MSD’s HIF-2 inhibitor Welireg (belzutifan) as an adjuvant treatment for RCC. Welireg was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback